TR201203732T1 - Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler. - Google Patents

Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler.

Info

Publication number
TR201203732T1
TR201203732T1 TR2012/03732T TR201203732T TR201203732T1 TR 201203732 T1 TR201203732 T1 TR 201203732T1 TR 2012/03732 T TR2012/03732 T TR 2012/03732T TR 201203732 T TR201203732 T TR 201203732T TR 201203732 T1 TR201203732 T1 TR 201203732T1
Authority
TR
Turkey
Prior art keywords
compositions
methods
skin diseases
treatment
opioid antagonists
Prior art date
Application number
TR2012/03732T
Other languages
English (en)
Inventor
Mustafa İskender Pisak İbrahi̇m
Bi̇ngöl Semra
Levent Selamoğlu Mehmet
Original Assignee
Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş. filed Critical Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş.
Publication of TR201203732T1 publication Critical patent/TR201203732T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş, deri hastalıklarının tedavisinde bir opioid antagonisti ya da farmasötik olarak kabul edilebilir bir tuzunun etkili bir miktarının ihtiyacı olan bir hastaya topikal olarak uygulanmasını içeren yöntemlere ilişkindir.
TR2012/03732T 2009-10-01 2010-09-28 Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler. TR201203732T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR200907463 2009-10-01

Publications (1)

Publication Number Publication Date
TR201203732T1 true TR201203732T1 (tr) 2012-09-21

Family

ID=43259699

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2012/03732T TR201203732T1 (tr) 2009-10-01 2010-09-28 Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler.

Country Status (4)

Country Link
US (1) US8323670B2 (tr)
EP (1) EP2482816B8 (tr)
TR (1) TR201203732T1 (tr)
WO (1) WO2011040894A1 (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2326387T3 (es) 2005-03-24 2009-10-08 Nolabs Ab Tratamiento cosmetico con oxido nitrico, dispositivo para llevar a cabo dicho tratamiento y procedimiento de fabricacion del mismo.
ES2475199T3 (es) * 2008-09-16 2014-07-10 Imuneks Farma Ila� Sanayi Ve Ticaret A.S. Uso de antagonistas opioides para la preparación de un medicamento en el tratamiento de enfermedades degenerativas de la retina
EP2482816B8 (en) 2009-10-01 2016-12-14 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Topical compositions of naltrexone for treating skin conditions
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
WO2013006608A1 (en) 2011-07-05 2013-01-10 Novan, Inc. Topical compositions
WO2013006613A1 (en) 2011-07-05 2013-01-10 Novan, Inc. Methods of manufacturing topical compositions and apparatus for same
US9283175B2 (en) 2011-07-28 2016-03-15 Ian S. Zagon Methods and compositions for treatment of epithelial wounds
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
WO2016022170A1 (en) 2014-08-08 2016-02-11 Novan, Inc. Topical emulsions
JP6513667B2 (ja) 2013-08-08 2019-05-15 ノヴァン，インコーポレイテッド 局所用組成物およびそれを使用する方法
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response
US10912743B2 (en) 2016-03-02 2021-02-09 Novan, Inc. Compositions for treating inflammation and methods of treating the same
US11166980B2 (en) 2016-04-13 2021-11-09 Novan, Inc. Compositions, systems, kits, and methods for treating an infection
GB202000167D0 (en) 2020-01-07 2020-02-19 Cytovation As Composition for treatment of neoplastic lesions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416886A (en) * 1981-07-29 1983-11-22 Dermall Limited Method of treating pruritis and composition therefor
US4888346A (en) 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US5356900A (en) * 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
US20030072724A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition to treat hyperpigmentation of the skin
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
US20030235542A1 (en) * 2002-06-21 2003-12-25 Maibach Howard I. Topical administration of pharmacologically active bases for skin lightening
US6821523B2 (en) * 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
ES2475199T3 (es) 2008-09-16 2014-07-10 Imuneks Farma Ila� Sanayi Ve Ticaret A.S. Uso de antagonistas opioides para la preparación de un medicamento en el tratamiento de enfermedades degenerativas de la retina
EP2482816B8 (en) 2009-10-01 2016-12-14 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Topical compositions of naltrexone for treating skin conditions
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.

Also Published As

Publication number Publication date
WO2011040894A1 (en) 2011-04-07
US8323670B2 (en) 2012-12-04
EP2482816B1 (en) 2016-10-05
EP2482816A1 (en) 2012-08-08
US20110082167A1 (en) 2011-04-07
EP2482816B8 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
TR201203732T1 (tr) Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler.
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
UA109921C2 (uk) ІМІДАЗО[4,5-c]ХІНОЛІН-2-ОН І ЙОГО ЗАСТОСУВАННЯ ЯК ПОДВІЙНОГО ІНГІБІТОРУ PІ3-КІНАЗИ/mTOR
CY1121646T1 (el) Παραγωγα μορφινανης για την αγωγη υπερβολικης δοσης ναρκωτικων
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
BR112013001122A2 (pt) composições ativas terapêuticas e seu método de uso
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201290919A1 (ru) Индазольные соединения и их применение
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
MX2011011596A (es) Perifosina y capecitabina como un tratamiento combinado para cancer.
WO2012050831A3 (en) Combination treatment for dermatological conditions
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201101533A1 (ru) Гетероциклические соединения в качестве ингибиторов mek
MX2013003638A (es) Tratamiento en combinacion para rosacea.
CY1117831T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη του καρκινου του μαστου
BR112013004850A2 (pt) tratamento de infarto do miocárdio usando antagonistas tgf-beta
UA111599C2 (uk) Композиція каспофунгіну